New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
April 29, 2022 - Supernus Pharmaceuticals announced the FDA approval of Qelbree (viloxazine), for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and olde
Download PDF
Return to publications
